bäkk in bisniss
insiderid taas ostmas
astusin eile välja
http://www.stock100.com/plotForecast.asp?symbol=PRCS&history=7&future=30
ei tea palju seda uskuda, aga täna võtsin topelt.
ei tea palju seda uskuda, aga täna võtsin topelt.
Sulgen pool positsioonist, kuna kardan, et siin võib asi veelgi halvemaks minna. Lootsin, et mõni suurem farma ostab nad ära või tehakse koostööleping, kuid tundub, et nad ei ole huvitatud.
Teine pool jääb pigem call optsiooniks.
Teine pool jääb pigem call optsiooniks.
Eile järelturul:
PRCS PRAECIS: Medicare to cover Praecis prostate cancer drug -- Reuters (1.41 -0.04)
Medicare will pay for Praecis Pharma's prostate cancer drug Plenaxis in certain patients, U.S. health officials said on Tuesday. The drug, known generically as abarelix, will be covered in men at advanced stages of the disease who do not want to undergo surgical castration and who cannot take certain other drugs. The patients would also have to suffer from severe bone pain, a risk of neurological problems and difficulty urinating in order for the Centers for Medicare and Medicaid Services (C.M.S.) to cover the injectable drug.
PRCS PRAECIS: Medicare to cover Praecis prostate cancer drug -- Reuters (1.41 -0.04)
Medicare will pay for Praecis Pharma's prostate cancer drug Plenaxis in certain patients, U.S. health officials said on Tuesday. The drug, known generically as abarelix, will be covered in men at advanced stages of the disease who do not want to undergo surgical castration and who cannot take certain other drugs. The patients would also have to suffer from severe bone pain, a risk of neurological problems and difficulty urinating in order for the Centers for Medicare and Medicaid Services (C.M.S.) to cover the injectable drug.
See on kindlasti hea uudis ning peaks aktsiat toetama. Hoian siiani poolt positsioonist ning ei kavatse juurde osta. Medicare'st üksi ei piisa, kuna tegu on natukene liiga suurte kõrvalmõjudega ravimiga. Usun, et Praecisele oleks hea, kui nad suudaks lepingu mõne suure farmaga sõlmida.
Kas ei tundu, et aktsia on 1,4 juures mõningase toetuse leidnud? Kui nüüd tuleks häid uudiseid, võiks ju tõesti pikaks minna...?
Soovitan ainult neil osta, kes ei pane suurt osa oma portfellist selle aktsia alla, nagu varem mainisin, pean seda nn. call optsiooniks, mille väärtus võib tulevikus olla olematu. Ise ostsin aktsiaid pärast seda, kui üks nõukogus olev tegelane ostis suure koguse aktsiaid.
Selline lõpp siis kogu lool:
PRCS PRAECIS confirms it will be acquired by GSK for $5.00 per share (1.99 ) -Update-
PRCS confirms that GSK will acquire all outstanding shares of PRAECIS' common stock for a cash purchase price of US $5.00 per share or a total of approximately $54.8 mln for the entire equity interest of PRCS.
PRCS PRAECIS confirms it will be acquired by GSK for $5.00 per share (1.99 ) -Update-
PRCS confirms that GSK will acquire all outstanding shares of PRAECIS' common stock for a cash purchase price of US $5.00 per share or a total of approximately $54.8 mln for the entire equity interest of PRCS.